“What we are trying to do more often is to ablate as much as we can,” said Shankar Siva, MBBS, PhD, FRANZCR, on pairing SABR with systemic therapy in RCC.
|Slideshows|February 25, 2015
Slide Show: Renal Cell Carcinoma
Author(s)OncoTherapy Network Staff
This slide show features various images of papillary, clear cell, chromophobe, and tubulocystic renal cell carcinoma.
Advertisement
Advertisement
Related to this article
Triplets did not beat pembrolizumab plus lenvatinib in frontline RCC, while belzutifan plus lenvatinib and perioperative pembrolizumab showed benefit.
Advertisement
Advertisement
Trending on CancerNetwork
1
Predicting Severe Immune-Related Toxicities in Lung Cancer Immunotherapy
2
Recapping GI Cancer at ESMO 2026: Standout Data From Phase 1 to Phase 3
3
EU Approves T-DXd for HER2+ Early Breast Cancer With Residual Disease
4
Outpatient Treatment-Related Toxicity After Hospital Discharge Among Patients Receiving Lifileucel for Advanced Melanoma
5